Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland

scientific article published on 30 November 2014

Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1019289712
P356DOI10.1186/S13561-014-0031-5
P932PMC publication ID4502065
P698PubMed publication ID26208931
P5875ResearchGate publication ID280387973

P2093author name stringFranz-Werner Dippel
Karlheinz Theobald
David Gasche
Andrea Lebioda
Stefan Plantör
P2860cites workIndividual patient-level and study-level meta-analysis for investigating modifiers of treatment effect.Q52971736
Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force ReportQ57542840
Network meta-analysis for indirect treatment comparisonsQ74720205
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsQ29619501
Meta-analysis of individual participant data: rationale, conduct, and reportingQ33530020
Methods in health service research. An introduction to bayesian methods in health technology assessmentQ33716256
Bayesian methods for evidence synthesis in cost-effectiveness analysisQ36381197
Direct versus indirect comparisons: a summary of the evidenceQ37133396
Use of indirect and mixed treatment comparisons for technology assessmentQ37259556
Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviewsQ37433313
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.Q37888895
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.Q46894544
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue1
P304page(s)31
P577publication date2014-11-30
P1433published inHealth Economics ReviewQ27724295
P1476titleRelevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
P478volume4

Reverse relations

cites work (P2860)
Q31133870Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified?
Q92062148Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
Q38670350First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany
Q89365659History and publication trends in the diffusion and early uptake of indirect comparison meta-analytic methods to study drugs: animated coauthorship networks over time
Q49887834INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY.
Q30240170Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.